加速器制备医用放射性同位素的现状与展望  

The Current Situation and Prospect of Accelerator Produced Medical Radioisotopes

作　　者：刘宁[1] 高靖 杨远友[1] 李飞泽[1] 廖家莉[1] LIU Ning;GAO Jing;YANG Yuanyou;LI Feize;LIAO Jiali(Key Laboratory of Radiation Physics and Technology of Ministry of Education,Institute of Nuclear Science and Technology,Sichuan University,Chengdu 610064,China)

机构地区：[1]四川大学原子核科学技术研究所辐射物理及技术教育部重点实验室,成都610064

出　　处：《同位素》2022年第5期424-438,I0004,共16页Journal of Isotopes

基　　金：四川省重大科技专项(2019ZDZX0004);国家自然科学基金(22006105);中国博士后基金(2020M683309);中央高校基本科研业务费资助项目。

摘　　要：加速器制备核素以其独特的自身优势成为制备放射性同位素的重要方式之一,在进入新世纪后作用与地位日益突出。本文对国内外加速器制备医用放射同位素技术的发展现状进行了简要概述,着重分析了^(18) F、^(64)Cu、^(68)Ge/^(68)Ga、^(89)Zr、^(111)In、^(211)At、^(225)Ac等重要医用放射性核素研究进展,并对我国加速器制备医用同位素的应用前景进行了展望。As one of the important ways to prepare radioisotopes,the role and status of accelerator produced nuclides have become increasingly prominent after entering the new century.In the present paper,a brief overview on development status of radioisotope preparation technology by accelerators at home and abroad was performed.In particular,the research progress of ^(18)F,^(64)Cu,^(68)Ge/^(68)Ga,^(89)Zr,^(111)In,^(211)At,^(225)Ac and other important medical radioisotope preparation technologies are introduced.The application prospects of isotopes prepared by domestic accelerators are also prospected.

关 键 词：医用放射性同位素 加速器制备 放射性药物 

分 类 号：TL921.1[核科学技术—核燃料循环与材料]